Advertisement


Bernard J. Escudier, MD, on RCC: Results From the CheckMate 214 Trial

2017 ESMO Congress

Advertisement

Bernard J. Escudier, MD, of Gustave Roussy, discusses efficacy and safety of nivolumab plus ipilimumab vs sunitinib for treatment-naïve advanced or metastatic renal cell carcinoma, including IMDC risk and PD-L1 expression subgroups (Abstract LBA5).



Related Videos

Gynecologic Cancers

Andrew R. Clamp, PhD, on Gynecologic Cancers: Results of the ICON8 Trial

Andrew R. Clamp, PhD, of The Christie NHS Foundation Trust, discusses his phase III study findings on dose-dense chemotherapy integration in first-line treatment of epithelial ovarian, fallopian tube, and primary peritoneal carcinoma (Abstract 929O).

Kidney Cancer

Bernard J. Escudier, MD, on RCC: Expert Perspective on Key Papers

Bernard J. Escudier, MD, of Gustave Roussy, offers a roundup of the important papers on renal cell cancer presented at this year's ESMO Congress.

Gynecologic Cancers

Mansoor Mirza, MD: Ovarian Cancer Treatment and Quality of Life

Mansoor Mirza, MD, of Copenhagen University Hospital, discusses quality of life in patients with recurrent ovarian cancer treated with niraparib (Abstract 930O).

Breast Cancer

Marleen Kok, MD, PhD, on Triple-Negative Breast Cancer: Results From the TONIC Trial

Marleen Kok, MD, PhD, of The Netherlands Cancer Institute, discusses findings from an adaptive phase II noncomparative trial of nivolumab after induction treatment in triple-negative breast cancer (Abstract LBA14).

Kidney Cancer

Robert A. Figlin, MD, on RCC: Results From the ADAPT Trial

Robert A. Figlin, MD, of Cedars-Sinai Medical Center, discusses an interim analysis of phase III findings on rocapuldencel-T, an individualized immunotherapy, for newly diagnosed patients with metastatic renal cell carcinoma (Abstract 1137O).

Advertisement

Advertisement




Advertisement